Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Axsome Therapeutics to $84 from $86 and keeps a Buy rating on the shares post the Q4 results. The firm says that while the update on AXS-05 in Alzheimer’s disease agitation disappointed, it came away positively from the company’s Q4 earnings call.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics price target lowered to $90 from $105 at Guggenheim
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Axsome Therapeutics expects cash to fund operations into cash flow positivity
- Axsome Therapeutics reports Q4 EPS ($1.41), consnesus ($1.14)
- Pharmanovia announces in-licensing agreement with Axsome for Sunosi
